Tom Wiggans
Board Member
Mr. Wiggans most recently served as Chairman of the Board of Directors and Chief Executive Officer of Peplin, Inc., a dermatology company acquired in 2009 by LEO Pharma A/S. Prior to Peplin, Mr. Wiggans was the Chief Executive Officer of Connetics Corporation from 1994 until its acquisition by Stiefel Laboratories, Inc. in December 2006; he was also Chairman of the Board of Connetics from January 2006 until its acquisition. From 1992 to 1994, Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics Inc. He served in various positions at the Ares-Serono Group from 1980 to 1992, including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans is currently the founding Chief Executive Officer of a new dermatology company backed by Bay City Capital and also serves as a Director of Onyx Pharmaceuticals, Sangamo Biosciences, Somaxon Pharmaceuticals and is Chairman of the Board at Excaliard Pharmaceuticals. Mr. Wiggans holds a B.S. in Pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University. [Back to Board]
